Remdesivir trial results show efficacy in Covid-19 treatment
The US National Institute of Allergy and Infectious Diseases has been running a trial of Remdesivir on 1,063 randomly assigned patients hospitalised with Covid-19. The group who got the Remdesivir treatment showed a median time of recovery of 11 days, while those who got a placebo averaged on a 15 day recovery. Mortality rate was 8% for the Remdesivir group and 11.6% for the placebo group.